Blueshift Asset Management, LLC Corcept Therapeutics Inc Transaction History

Blueshift Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$17.33 - $25.3 $293,864 - $429,012	-16,957 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$16.53 - $25.21 $280,299 - $427,485	16,957 New	16,957 $382,000
Q4 2021 Feb 11, 2022	SELL	$17.1 - $23.34 $300,378 - $409,990	-17,566 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$19.68 - $22.53 $241,217 - $276,150	-12,257 Reduced 41.1%	17,566 $346,000
Q2 2021 Aug 13, 2021	BUY	$19.97 - $24.43 $252,440 - $308,819	12,641 Added 73.57%	29,823 $656,000
Q1 2021 May 06, 2021	BUY	$23.49 - $30.56 $403,605 - $525,081	17,182 New	17,182 $409,000
Q1 2020 May 14, 2020	SELL	$10.11 - $14.04 $269,613 - $374,418	-26,668 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $321,616 - $452,289	26,668 New	26,668 $323,000

350

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.92B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.